Hydroxyzine is a first-generation antihistamine prescribed off-label at 10mg to 50mg for insomnia and anxiety, working by blocking histamine H1 receptors in the brain. It is not a controlled substance and carries no dependence risk, and tolerance to its sedating effect commonly develops within days to weeks. Its main drawback is anticholinergic activity, which causes dry mouth, constipation, urinary retention, and confusion, and which cumulative exposure studies have associated with increased dementia risk in older adults. It appears on the Beers Criteria list of medications to avoid in adults over 65.
TL;DR: Hydroxyzine is an old allergy medicine that makes you drowsy, so doctors use it for sleep and for anxiety. It is not addictive and it is not a controlled substance, which is why it gets chosen. Two things you should know. First, most people stop feeling the sedation within days to weeks, because your body adapts fast. Second, it is an anticholinergic, and long-term use of anticholinergic medicines has been linked to higher dementia risk in older adults. That is a reason to treat it as a short-term tool and not a nightly habit. It is on the list of drugs to avoid in people over 65. If you have been taking one of these every night for years, that is worth a conversation. Tell Dr. Ash.
Hydroxyzine gets picked for the same reason trazodone does: it is uncontrolled, it is cheap, and it creates no dependence.
The cost is different from the one people expect, and it is a slow one.
What is hydroxyzine and how does it work?
Hydroxyzine is a first-generation antihistamine, approved for itching from allergic conditions and for anxiety, and prescribed off-label for insomnia. It is sold as hydroxyzine hydrochloride and hydroxyzine pamoate, which behave similarly for this purpose.
The sedation comes from blocking histamine H1 receptors in the brain. Histamine is one of the wake-promoting neurotransmitters, so blocking it produces drowsiness, which is the same mechanism that makes diphenhydramine sedating. Unlike newer antihistamines such as cetirizine or loratadine, hydroxyzine crosses the blood-brain barrier readily, which is what makes it useful here and also what carries the cost.
It also has anticholinergic activity, blocking muscarinic receptors, and that is the part of its profile that deserves the most attention.
What dose is used for sleep?
10mg to 50mg at bedtime, with 25mg a common starting point.
Onset is 30 to 60 minutes, so it is taken roughly an hour before bed. The half-life is around 20 hours in healthy adults and considerably longer in older adults, which is why next-day sedation is a frequent complaint and why the dose should start low.
Higher doses do not reliably produce better sleep. They produce more anticholinergic effect and more morning hangover.
Why does it stop working?
Because the histamine system adapts, and it adapts quickly.
Tolerance to the sedating effect of H1 antihistamines develops within days to a few weeks in most people. This is well described for diphenhydramine and applies to the class. What people experience is a drug that worked beautifully for a fortnight and then did nothing, followed by the temptation to increase the dose, which buys a little more sedation and considerably more of the anticholinergic effects.
That tolerance is the strongest argument for treating hydroxyzine as a short bridge instead of a long-term plan. A medication that predictably stops working is a poor foundation for a chronic condition, and chronic insomnia needs a treatment that lasts.
Guidance from the Clinic
What is the anticholinergic problem?
It is the part of this drug's profile that almost nobody discusses, and it is the reason to be careful about years of nightly use.
Anticholinergic medications block acetylcholine, a neurotransmitter involved in memory, attention, and a long list of ordinary body functions. In the short term that produces dry mouth, constipation, blurred vision, difficulty urinating, and in older adults confusion.
The longer-term signal is the one that matters. Large observational studies have found an association between cumulative anticholinergic exposure and later dementia diagnosis. A prospective cohort published in 2015 found higher dementia risk with higher cumulative use, and a large nested case-control study in 2019 found similar associations for several anticholinergic classes. These are observational and cannot prove causation, and confounding by indication is a serious limitation, and the signal has been consistent enough to change prescribing guidance.
Practically: hydroxyzine appears on the American Geriatrics Society Beers Criteria as a medication to avoid in adults 65 and over, on the grounds of anticholinergic effects, sedation, and fall risk. Anyone already taking other anticholinergic drugs, and there are many, from bladder medications to some antidepressants, is adding to a total burden that is worth counting.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
None of this makes a two-week course dangerous. It makes a six-year nightly habit worth reconsidering.
What are the other side effects?
Next-day sedation, from the long half-life, particularly in older adults.
Dry mouth, constipation, blurred vision, urinary retention, from the anticholinergic activity.
QT prolongation. Hydroxyzine can prolong the QT interval, so it should be avoided with other QT-prolonging drugs and in anyone with a known prolonged QT, significant bradycardia, or electrolyte abnormalities.
Confusion and falls in older adults, which is the combination that turns a sleep aid into a fracture.
Paradoxical agitation, uncommon and more likely in children and older adults.
Who should avoid it?
Adults over 65, per the Beers Criteria, unless there is a specific reason and the alternatives have been considered. Anyone with narrow-angle glaucoma, significant prostatic enlargement with urinary retention, or a known QT prolongation. Anyone taking other QT-prolonging medication. Pregnancy, where it is generally avoided.
Caution and a conversation apply to anyone already carrying a meaningful anticholinergic load, anyone with dementia or mild cognitive impairment, and anyone whose insomnia has not been screened for apnea. That last point applies to every sedating drug and is covered on insomnia or sleep apnea.
How does it compare with the alternatives?
Against doxepin at low dose, hydroxyzine loses on evidence. Low-dose doxepin is FDA-approved for sleep maintenance insomnia and is a far more selective H1 blocker with minimal anticholinergic activity at 3mg to 6mg, which is covered on doxepin for sleep.
Against trazodone, the two are comparable in evidence quality and differ in side-effect profile: trazodone brings orthostatic hypotension and rare priapism, hydroxyzine brings anticholinergic burden and faster tolerance. Trazodone for sleep has that picture.
Against over-the-counter diphenhydramine, which is the same mechanism and the same problems, hydroxyzine offers no clear advantage other than being prescribed and therefore reviewed by someone.
Against CBT-I, it loses outright for chronic insomnia, and the guidelines say so.
Key Takeaways
- Hydroxyzine sedates by blocking histamine H1 receptors, the same pathway as older allergy medicines.
- Tolerance to that sedation develops within days to weeks, so it works poorly as a long-term plan.
- Its anticholinergic activity is the underrated cost, and cumulative exposure has been associated with dementia risk in older adults.
- It is on the Beers Criteria list of medications to avoid in adults 65 and over.
- Low-dose doxepin achieves similar sedation with far less anticholinergic burden and an FDA approval it holds.
Related at Fishtown Medicine
Scientific References
- American Geriatrics Society. Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
- Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Internal Medicine. 2015;175(3):401-407.
- Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia. JAMA Internal Medicine. 2019;179(8):1084-1093.
- Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine. 2017;13(2):307-349.
- US Food and Drug Administration. Vistaril (hydroxyzine pamoate) prescribing information. FDA Access Data.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.